News & Updates

Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
21 Oct 2024 byAudrey Abella

In a real-world analysis evaluating four oral antiviral agents for the treatment of COVID-19, two ritonavir-based regimens fared better than molnupiravir and azvudine in reducing hospital stay among patients hospitalized for mild or moderate disease.

Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
21 Oct 2024
WTAP overexpression tied to poor outcomes in NSCLC
WTAP overexpression tied to poor outcomes in NSCLC
18 Oct 2024
Bedaquiline-containing regimens show sustained benefit in rifampicin-resistant TB
Bedaquiline-containing regimens show sustained benefit in rifampicin-resistant TB
16 Oct 2024 byJairia Dela Cruz

In the treatment of patients with rifampicin-resistant tuberculosis (TB), two bedaquiline-containing regimens, namely a 9-month all-oral regimen and a shorter 6-month regimen with 8 weeks of aminoglycoside, maintains superior efficacy to a 9-month injectable regimen through 132 weeks, according to long-term data from the STREAM 2 trial.

Bedaquiline-containing regimens show sustained benefit in rifampicin-resistant TB
16 Oct 2024
Sexual dysfunction prevalent in women with PAH
Sexual dysfunction prevalent in women with PAH
15 Oct 2024

Many women with pulmonary arterial hypertension (PAH) with a mild functional impairment suffer from sexual dysfunction, a recent study claims.

Sexual dysfunction prevalent in women with PAH
15 Oct 2024